Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalmefene for improving recovery quality after general anesthesia
ChiCTR2000035846Phase 4Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Anesthesia-related recovery impairment (ARRI) comparing Nalmefene 0.25 µg/kg with Placebo (normal saline) (2 arms). Primary endpoint: Time from end of surgery to Aldrete score ≥ 9. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
nalmefene
03
Conditions
Anesthesia-related recovery impairment (ARRI)
Beyond the preview
Go deeper on ChiCTR2000035846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035846.